<DOC>
	<DOCNO>NCT00028964</DOCNO>
	<brief_summary>RATIONALE : Herbs use traditional Chinese medicine may decrease side effect chemotherapy . PURPOSE : Randomized phase I/II trial study effectiveness herb use traditional Chinese medicine decrease side effect chemotherapy surgery woman stage I , stage II , early stage III breast cancer .</brief_summary>
	<brief_title>Combination Chemotherapy After Surgery With Without Chinese Herbal Therapy Treat Symptoms Women With Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect safety chinese herbal therapy ( CHT ) administer toxicity attenuation combination adjuvant doxorubicin cyclophosphamide woman stage I , II , early stage III breast cancer . - Determine patient compliance feasibility use CHT daily treatment calendar , weekly symptom inventory , quality life mood state questionnaire complete patient . - Determine patient preference concern CHT . - Determine , preliminarily , efficacy CHT ameliorate toxic effects/side effect adjuvant chemotherapy doxorubicin cyclophosphamide , term incidence severity adverse event , patient . OUTLINE : This randomize , placebo-controlled , double-blind study . Patients randomize one two treatment arm . - Arm I : Patients receive adjuvant doxorubicin IV cyclophosphamide IV 1 hour day 0 , 21 , 42 , 63 . Patients also receive oral chinese herbal therapy three time daily day -10 105 . - Arm II : Patients receive adjuvant chemotherapy arm I oral placebo three time daily day -10 105 . Quality life assess baseline day 3 , 24 , 45 , 66 , 84 , 105 . Patients follow day 105 . PROJECTED ACCRUAL : A total 60 patient ( 30 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage I , II , early stage III breast cancer adjuvant doxorubicin cyclophosphamide recommend No metastatic disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Over 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Hemoglobin least 9.0 g/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST great 2 time normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No evidence acute ischemic cardiac disease ECG Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history multiple severe food medicine allergy sensitivities No medical psychological condition would preclude study participation No severe concurrent illness PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent hormonal therapy Radiotherapy : At least 3 week since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : At least 3 week since prior investigational agent At least 3 week since prior herbal therapy No concurrent investigational agent No concurrent herbal therapy alternative medicine Concurrent acupuncture allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
</DOC>